This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug
by Zacks Equity Research
The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.
CTLT or NBIX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CTLT vs. NBIX: Which Stock Is the Better Value Option?
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CTLT vs. NBIX: Which Stock Is the Better Value Option?
Neurocrine Biosciences (NBIX) Beats Q4 Earnings Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 35.71% and -0.84%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Neurocrine Biosciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Neurocrine Biosciences, Inc.
4 Defensive Stocks to Buy Amid Shutdown and Brexit
by Zacks Equity Research
Defensive equities could ride out market unpredictability.
Neurocrine Gives Ingrezza Sales View, Updates on Pipeline
by Zacks Equity Research
Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.
Do Options Traders Know Something About Neurocrine Biosciences (NBIX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.
Neurocrine (NBIX) Catches Eye: Stock Jumps 6.5%
by Zacks Equity Research
Neurocrine (NBIX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 8.33% and 0.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
by Zacks Equity Research
We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Neurocrine (NBIX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are expected to focus on Neurocrine's (NBiX) updates on its pipeline candidates when it reports third-quarter results.
Neurocrine Biosciences (NBIX) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Inks Deal with Private Biotech to Make CNS Drugs
by Zacks Equity Research
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis
by Zacks Equity Research
AbbVie (ABBV) and Neurocrine receive Canadian approval for Orilissa, for the treatment of moderate to severe pain associated with endometriosis.
UTHR vs. NBIX: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. NBIX: Which Stock Is the Better Value Option?
Bayer Starts Phase III Study for Uterine Fibroids' Candidate
by Zacks Equity Research
Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.
Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug
by Zacks Equity Research
Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD).
Company News for April 13, 2017
by Zacks Equity Research
Companies in the News are: BBRY,QCOM,VAL,AXTA,NBIX,NAK
Here's Why Neurocrine (NBIX) Stock is Soaring 24% Today
by Parth Panchal
Neurocrine Biosciences (NBIX), a San Diego based biotechnology company, is soaring today on FDA approval of their drug INGREZZA (valbenazine).
Repros' Proellex Continues to be Under Partial Clinical Hold
by Zacks Equity Research
Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver
AbbVie's Elagolix Meets Primary Endpoint in Phase II Study
by Zacks Equity Research
AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.